Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04821752
Other study ID # 20-1672
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2022
Est. completion date September 1, 2024

Study information

Verified date July 2022
Source Bastyr University
Contact Amber Coggins
Phone 425 602 3000
Email acoggins@bastyr.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to test whether non-persistent environmental chemicals (PECs) are elevated in people with glucose dysregulation. The primary aim is to measure whether this toxicant burden can be reduced using a dietary and lifestyle modification intervention. The secondary aim is to observe any changes in glucose response pre and post-intervention.


Description:

The primary aim will be measured using a commercially-available screening test for urinary toxicant metabolites. The toxicant burden will be measured by a percentile score of each metabolite and summing all percentile values. A risk level of each metabolite will be normalized by the percentile score in order to calculate the total toxic burden for an individual. Wilcoxon-ranked sum non-parametric calculations will be used to evaluate whether pre and post-intervention reduction has occurred. Because this is a single-arm trial, any reduction in the toxicant burden will be correlated with the relative improvement of the secondary endpoint and will be measured using Kendall's tau-beta ranked correlation. The secondary aim will assess each participant's fasting and post-prandial glucose response measured daily for throughout the 3-week trial.. Because this study is not powered, the estimated man reduction from baseline cannot be estimated. Any reduction in blood glucose mean values will allow us to calculate an effect size for future investigation. The ranking of the improvement in glucose response (AUC) will be tested by ranking the reduction of the toxic burden by a correlation analysis using Kendall's tau-beta ranked correlation described above. Each participant is provided with a baseline in-person assessment, one midpoint education session and a final assessment session. Each participant will receive a standardized packet of information regarding dietary and lifestyle interventions which reduce toxicant exposures along with a water filter for home use and gift card to support the purchase of organic food during the trial. Questionnaries including a Medical Symptom Questionnaire, Weekly Stress Inventory and Knowledge Atttitudes and Behavior Questionnaire will be administered pre and post-intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date September 1, 2024
Est. primary completion date September 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. 18 years old or older 2. Able to complete the remote informed consent process. 3. Glucose dysregulation with HbA1c >= 5.7% at baseline 4. If HgA1c is greater than 6.5% and the potential participant is not already receiving standard care for diabetes from a physician, participants must see their primary care provider for diabetes standard care before enrollment in the study. 5. Those not already eating a majority organic-food diet and drinking filtered water (>50% by self-disclosure) Exclusion Criteria 1. Use of insulin or insulin analog medications 2. Planning to have elective surgery, diagnostic procedures, dental, or cosmetic procedures during the study period 3. Unable or unwilling to modify dietary and lifestyle behaviors 4. Those already eating a majority organic-food diet and drinking filtered water (>50% by self-disclosure)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Avoidance Education
Dietary modification and lifestyle interventions

Locations

Country Name City State
United States Bastyr University Kenmore Washington

Sponsors (1)

Lead Sponsor Collaborator
Bastyr University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in percentile score of urinary excretion of toxicant marker metabolites pre and post three-week dietary and lifestyle intervention The primary aim will be measured using a commercially-available screening test for urinary toxicant metabolites. The toxicant burden will be measured by a percentile score of each metabolite and summing all percentile values. A risk level of each metabolite will be normalized by the percentile score in order to calculate the total toxic burden for an individual. Wilcoxon-ranked sum non-parametric calculations will be used to evaluate whether pre and post-intervention reduction has occurred. Because this is a single-arm trial, any reduction in the toxicant burden will be correlated with the relative improvement of the secondary endpoint and will be measured using Kendall's tau-beta ranked correlation. 3 months
Secondary Change in immediate glucose response measured by daily fasting and post-prandial blood glucose measurements. A secondary endpoint is to observe each participant's glucose response throughout the 3-week trial period. Because this is not powered, the estimated mean reduction from the baseline to the ending of the trial cannot be estimated. Any reduction in the blood glucsoe mean values allows us to calculate the effect size for future investigation. The ranking of the improvement in glucose response (smaller AUC) is tested with the ranking of the reduction of toxic burden by a correlation analysis described the above. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Not yet recruiting NCT01402362 - Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study. N/A
Completed NCT01671293 - Multicomponent Telecare Model for Supporting Prediabetes Patients N/A
Completed NCT00740363 - Sitagliptin in Renal Transplant Recipients Phase 4
Completed NCT00436475 - Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes Phase 1/Phase 2
Completed NCT04090788 - The Effect of Momordica Charantia Supplementation on Blood Glucose Levels N/A
Active, not recruiting NCT05460884 - Effects of Seaweed Extract on Postprandial Response to White Bread N/A
Completed NCT03348020 - Iron and Insulin Resistance in Overweight and Obese Humans N/A
Terminated NCT03356873 - Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX) N/A
Completed NCT03922685 - Effects of Diet and Exercise on Circadian Glycemia N/A
Completed NCT03730727 - Exercise-meal Timing and Postprandial Glucose Control N/A
Completed NCT04743960 - Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition N/A
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Terminated NCT01887691 - Sleep Effectiveness and Insulin and Glucose Homeostasis Phase 1
Completed NCT02412995 - The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite Phase 0
Not yet recruiting NCT01436448 - Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy Phase 3
Completed NCT00862589 - Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM) N/A